Skip to main content

27-05-2020 | Multiple sclerosis | Video

EAN 2020 | Ongoing reporting supports long-term safety of ocrelizumab in MS

Stephen Hauser reports the ongoing safety data for ocrelizumab in patients with relapsing or primary progressive multiple sclerosis, including preliminary post-marketing experience of a small group of patients with COVID-19 (5:13).

Funding for independent interviews at EAN 2020 was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.